LC-MS raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-06-02 and is reviewed periodically as new material appears.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
As of 2018, research has paid insufficient attention to the potential adverse effects of carbohydrate restricted dieting, particularly for micronutrient sufficiency, bone health and cancer risk. One low-quality meta-analysis reported that adverse effects could include "constipation, headache, halitosis, muscle cramps and general weakness". In a comprehensive systematic review of 2018, Churuangsuk and colleagues reported that other case reports give rise to concerns of other potential risks of low-carbohydrate dieting including hyperosmolar coma, Wernicke's encephalopathy, optic neuropathy from thiamine deficiency, acute coronary syndrome and anxiety disorder. Significantly restricting the proportion of carbohydrate in diet risks causing malnutrition, and can make it difficult to get enough dietary fiber to stay healthy. As of 2014, it appeared that with respect to the risk of death for people with cardiovascular disease, the kind of carbohydrates consumed are important; diets relatively higher in fiber and whole grains lead to reduced risk of death from cardiovascular disease compared to diets high in refined grains.
=== Palmar and plantar aponeuroses and extensor hood === The palmar aponeuroses occur on the palms of the hands. The extensor hoods are aponeuroses at the back of the fingers. The plantar aponeuroses occur on the plantar aspect of the foot. They extend from the calcaneal tuberosity then diverge to connect to the bones, ligaments and the dermis of the skin around the distal part of the metatarsal bones.
First Minister of Wales Eluned Morgan is appointed a Privy Councillor. 29 August – Starmer confirms that the UK government is considering introducing tougher measures on outdoor smoking in order to reduce the number of tobacco-related deaths. Colum Eastwood announces he will resign as leader of the Social Democratic and Labour Party, triggering a leadership election. 30 August – A review is launched into Starmer's appointments of Labour donors to senior civil service jobs following allegations of cronyism. Conservative MP Esther McVey is criticised as "repugnant" by Jewish groups for sharing part of "First They Came", Martin Niemoller's 1946 poem about the Holocaust, in a tweet voicing her opposition to proposed new bans on outdoor smoking. McVey insists she was not equating the bans with Nazi persecution of the Jews, and says "no offence was ever intended". It is reported that Starmer has moved a portrait of Margaret Thatcher from her former 10 Downing Street study to elsewhere in the building. He subsequently says that he moved the portrait because he "didn’t want a picture of anyone" in his study and prefers landscapes. 2024 Ulster Unionist Party leadership election: After nominations close, Mike Nesbitt is the only candidate to put their name forward, and will be ratified as the party's next leader at a meeting on 14 September. During a closed-door session at the SNP Party Conference, leader John Swinney tells delegates the party's losses at the election occurred because it spent too much time focusing on the "process of independence".
2-Hydroxybutyrate, the conjugate base of 2-hydroxybutyric acid, is produced in mammalian tissues (principally hepatic) that catabolize L-threonine or synthesize glutathione. Oxidative stress or detoxification demands can dramatically increase the rate of hepatic glutathione synthesis. Under such metabolic stress conditions, supplies of L-cysteine for glutathione synthesis become limiting, so homocysteine is diverted from the transmethylation pathway forming methionine into the transsulfuration pathway forming cystathionine. 2-Hydroxybutyrate is released as a byproduct when cystathionine is cleaved to cysteine that is incorporated into glutathione. Chronic shifts in the rate of glutathione synthesis may be reflected by urinary excretion of 2-hydroxybutyrate. α-hydroxybutyrate may be useful as an early indicator of insulin resistance in non-diabetic subjects. Moreover, elevated serum α-hydroxybutyrate predicts worsening glucose tolerance.
Sources: en.wikipedia.org
Cytochrome P450 (CYP) ω-hydroxylases are enzymes that play a role in the metabolism of fatty acids and their derivatives. These enzymes add a hydroxyl group to the ω- or (ω-1)-C atom of substrates such as arachidonic acid, docosahexaenoic acid, eicosapentaenoic acid, leukotrienes, and prostaglandins. The metabolites produced by CYP ω-hydroxylases, particularly 20-HETE, have been found to have pleiotropic effects in inflammation and many inflammation-associated diseases. These enzymes are part of the larger family of CYP enzymes that mediate oxidation reactions in the human body. They are mainly expressed in various tissues and organs, including the liver, kidney, lung, endothelial cells, platelets, and immunocytes. The expression levels of CYP ω-hydroxylases can be influenced by gender and inflammatory stimuli.
== Development == The mod was developed by Adrian Finol in 2000. Finol created a unique mod that focused on intense, fast paced game-play that set it apart from other total conversion mods. Finol's goal was to create an online first person shooter that was more 'team based' than Counter-Strike, with bonuses for acting with team mates. Several versions were created under Finol's lead, each one adding new features and tweaking the game-play. In late 2001, Finol handed the FLF torch to Dave Dynerman so that he could start a new career with Valve Corporation. Several key contributors of the original FLF team now work for Valve. Under the lead of Dynerman, FLF went through several upgrades, resulting in even more versions. Dynerman went on to join Raven Software early in 2003 and Tony Sergi took over as the lead coder. Sergi created many versions for FLF, although not all became public. As the release of Half-Life 2 approached Sergi, along with the development team, faced a difficult decision. A great deal of time and work from all aspects had gone into the most recent unreleased versions of FLF (1.9 and Defiance), but the mod would have a hard time competing with other mods that were moving to the Half-Life 2 Source engine. Faced with a declining player base and only a handful of members left, the development team with real lifetime constraints for some, put further FLF work on hold.
Bate-Smith, E. C. (Sep 1954). "Leuco-Anthocyanins". Biochem. J. 58 (1): 122–125. doi:10.1042/bj0580122. PMC 1269852. PMID 13198862. Pecket, R.C. Constituents of Leaf Extracts ... , New Phytologist 1959 Oct; 58(2) (retrieved 27 sept 2010 http://onlinelibrary.wiley.com/doi/10.1111/j.1469-8137.1959.tb05350.x/pdf ) Stecher, G. and Bonn, G. K., Phytochemical Analysis, Chromatography, Elsevier Science, E. Heftmann (ed), Amsterdam, pp. 1050. ISBN 0-444-51108-3 (2004) (retrieved via google books 9/27/2010)
=== Parliaments of the Union === 1st South African Parliament (1910–1915) – majority party: South African Party 2nd South African Parliament (1915–1920) – majority party: South African Party 3rd South African Parliament (1920–1921) – majority party: South African Party 4th South African Parliament (1921–1924) – majority party: South African Party 5th South African Parliament (1924–1929) – majority party: National Party 6th South African Parliament (1929–1933) – majority party: National Party 7th South African Parliament (1933–1938) – majority party: United Party 8th South African Parliament (1938–1943) – majority party: United Party 9th South African Parliament (1943–1948) – majority party: United Party 10th South African Parliament (1948–1953) – majority party: National Party 11th South African Parliament (1953–1958) – majority party: National Party 12th South African Parliament (1958–1961) – majority party: National Party
Familial intrahepatic cholestasis (FIH) is a group of disorders that lead to intrahepatic cholestasis in children. Most often, FIH occurs during the first year of life, with an incidence rate of 1/50,000 to 1/100,000. There are three different versions of FIH, with each causing a different severity of jaundice. Typically, children exhibit recurrent jaundice episodes, which eventually become permanent. Diagnosis usually occurs by analyzing laboratory features, liver biopsy results, DNA/RNA sequences, and biliary lipid analysis. The definitive treatment for FIH is liver transplant which usually results in a high recovery rate. Each type of FIH is a result of a different mutation. The three genes thought to be involved include APT8B1, which encodes for the FIC1 protein. The ABCB11 gene encodes for the bile salt export pump (BSEP) protein, and the ABCB4 gene encodes for the multidrug resistance 3 (MDR3) protein. BSEP and MDR3 are respectively responsible for transporting bile salt and phospholipid, two major constituents of bile, across the apical membrane of hepatocytes.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.